Skip to main content
Lilly to pay $8M to Zymeworks for immuno-oncology drug milestone

Zymeworks will receive an $8 million milestone payment from Eli Lilly and Co. resulting from Lilly's investigational new drug application for an immuno-oncology bispecific antibody based on the Azymetric platform from Zymeworks as part of the companies' 2014 deal.

Full Story: